Literature DB >> 15503049

PET and prostate cancer.

G Sanz1, J Rioja, J J Zudaire, J M Berián, J A Richter.   

Abstract

The diagnosis of prostate cancer leaves some questions without answers. The different diagnostic techniques are limited in three situations: (1) staging of the tumour: identification of node involvement, (2) quantification of the tumour volume and its location inside the gland, (3) premature identification of relapse after radical treatment. These are the three problems that we need to consider in the diagnosis of prostate carcinoma. Imaging techniques can tell us the morphological alterations in the structures and organs. Positron emission tomography (PET) introduces a new way of identifying damage by counting metabolic activity. The tracers are substances that are marked with a radioactive molecule that is picked up more readily by the tumours. The presence of these substances in a set anatomic zone means higher consumption and therefore more metabolic activity. The radiotracer most frequently used in PET is glucose marked with fluoride 18. The first studies with marked glucose and prostate tumours started at the end of the 1990s. There are many contradictions in the results of these studies due to renal elimination, which produces an accumulation in the urinary tract and does not correctly show the prostate zone and iliobturator nodes area, and its capitation by zones with inflammatory process or prostatic hyperplasia. Choline is a substance that is present in cellular membranes. When it is marked with carbon 11, it changes to a new tracer. This radiotracer has affinity with prostate damage and allows the better differentiation of malignant from benign processes. It also has the advantage of the absence of renal elimination. Trials that used choline marked with carbon 11 (11C choline) are beginning to obtain very promising results. This union of a method that identifies metabolic activity with an imaging technique increases the sensitivity in the diagnostic test and can help find the exact location of the 11C choline deposits. The PET-CT combines the PET with computerised tomography. The 11C choline PET-CT is presented as a promising technique for answering the three problems mentioned above.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15503049     DOI: 10.1007/s00345-004-0418-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  8 in total

1.  [Solitary lung metastasis after radical prostatectomy].

Authors:  J López Ferrandis; J Boán García; J Rioja Zuazu; J M Regojo Balboa; J M Fernández Montero; D Sánchez Zalabardo; J M Berián Polo; J J Zudaire Bergera; D Rosell Costa; J E Robles García
Journal:  Actas Urol Esp       Date:  2003-09       Impact factor: 0.994

2.  Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

Authors:  M Picchio; C Messa; C Landoni; L Gianolli; S Sironi; M Brioschi; M Matarrese; D V Matei; F De Cobelli; A Del Maschio; F Rocco; P Rigatti; F Fazio
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

3.  Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.

Authors:  Igle J de Jong; Jan Pruim; Philip H Elsinga; Willem Vaalburg; Han J Mensink
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

4.  Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer.

Authors:  I J Liu; M B Zafar; Y H Lai; G M Segall; M K Terris
Journal:  Urology       Date:  2001-01       Impact factor: 2.649

5.  Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer.

Authors:  G Sanz; J E Robles; M Giménez; J Arocena; D Sánchez; F Rodriguez-Rubio; D Rosell; J A Richter; J M Berián
Journal:  BJU Int       Date:  1999-12       Impact factor: 5.588

Review 6.  Positron emission tomography in prostate and renal cell carcinoma.

Authors:  Dana Mathews; Orhan K Oz
Journal:  Curr Opin Urol       Date:  2002-09       Impact factor: 2.309

7.  PET imaging of prostate cancer using carbon-11-choline.

Authors:  T Hara; N Kosaka; H Kishi
Journal:  J Nucl Med       Date:  1998-06       Impact factor: 10.057

8.  11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.

Authors:  I J de Jong; J Pruim; P H Elsinga; W Vaalburg; H J A Mensink
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

  8 in total
  10 in total

1.  [Cost considerations for whole-body MRI and PET/CT as part of oncologic staging].

Authors:  C Plathow; M Walz; M P Lichy; P Aschoff; C Pfannenberg; H Bock; S M Eschmann; C D Claussen; H P Schlemmer
Journal:  Radiologe       Date:  2008-04       Impact factor: 0.635

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

3.  (11)C-acetate PET in the early evaluation of prostate cancer recurrence.

Authors:  Susanne Albrecht; Franz Buchegger; Dmitri Soloviev; Habib Zaidi; Hansjoerg Vees; Haleem G Khan; Alain Keller; Angelika Bischof Delaloye; Osman Ratib; Raymond Miralbell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-11       Impact factor: 9.236

4.  Utility of F-18 fluorodeoxyglucose posıtron emıssıon tomography/computed ın carcınoma of unknown primary.

Authors:  Umut Elboga; Selim Kervancioğlu; Ertan Sahin; Mustafa Basibuyuk; Y Zeki Celen; Cumali Aktolun
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

Review 5.  Management strategies for locally advanced prostate cancer.

Authors:  Ashesh B Jani
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Breast cancer clinical and translational research: analogies and implications for prostate cancer.

Authors:  Lea Baer; Silvia C Formenti
Journal:  Rev Urol       Date:  2007

7.  Choline autoradiography of human prostate cancer xenograft: effect of castration.

Authors:  Hossein Jadvar; Alparslan Gurbuz; Xiankui Li; Antranik Shahinian; Peter S Conti
Journal:  Mol Imaging       Date:  2008 May-Jun       Impact factor: 4.488

Review 8.  Diagnosis of prostate cancer via nanotechnological approach.

Authors:  Benedict J Kang; Minhong Jeun; Gun Hyuk Jang; Sang Hoon Song; In Gab Jeong; Choung-Soo Kim; Peter C Searson; Kwan Hyi Lee
Journal:  Int J Nanomedicine       Date:  2015-10-19

9.  11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.

Authors:  Cristina Nanni; Elena Zamagni; Michele Cavo; Domenico Rubello; Paola Tacchetti; Cinzia Pettinato; Mohsen Farsad; Paolo Castellucci; Valentina Ambrosini; Gian Carlo Montini; Adil Al-Nahhas; Roberto Franchi; Stefano Fanti
Journal:  World J Surg Oncol       Date:  2007-06-20       Impact factor: 2.754

10.  Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.

Authors:  Nerissa Therese Viola-Villegas; Kuntal K Sevak; Sean D Carlin; Michael G Doran; Henry W Evans; Derek W Bartlett; Anna M Wu; Jason S Lewis
Journal:  Mol Pharm       Date:  2014-05-06       Impact factor: 4.939

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.